Charles Chansik Hong, MD
Director of Cardiology Research
About Charles Chansik Hong, MDToggle accordion item
Dr. Charles (Chaz) Hong is a physician-scientist whose research functions at the intersection of developmental biology, chemical biology, stem cell biology, and cardiovascular medicine. Dr. Hong’s work includes innovative chemical biologic approaches to study embryonic development as well as implementation of the induced pluripotent stem cell (iPSC) technology to better understand human cardiomyocyte biology and pathobiology at the cellular level.
His research has made important contributions to the emerging field of chemical genetics through the discovery of chemical modulators of several key developmental pathways, including the first small molecule inhibitor of bone morphogenetic protein (BMP). Dr. Hong’s research has revealed both novel biological insights and new therapeutic opportunities. For example, his BMP inhibitor technology has been licensed toward clinical development of breakthrough therapies for devastating diseases. In addition, Dr. Hong edited one of the first books focused on the role of chemical biology in stem cell and regenerative medicine, and a book covering the latest methods and protocols in chemical biology. His research has also made important contributions toward the utilization of human iPSC-derived cardiomyocytes (hiPSC-CMs) as an in vitro model for the study of human cardiomyocyte physiology. His clinical expertise is in cardiovascular genetics.
Prior to joining the University of Maryland School of Medicine, he was on faculty at Harvard Medical School and Vanderbilt University School of Medicine, where he co-directed Center for Inherited Heart Disease and chaired Accelerating Drug Repositioning/Repurposing Incubator.
Lab Website: http://www.medschool.umaryland.edu/hong-lab/
University of Maryland Medical Center
EducationToggle accordion item
Yale University School of Medicine, 1998
Yale-New Haven Hospital, 2001
Massachusetts General Hospital - Cardiovascular Disease, 2005